INT151000

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.35
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 5.13
Pain Relevance 2.20

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Anatomy Link Frequency
parietal cell 2
chest 1
vesicle 1
Atp12a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cINOD 81 99.44 Very High Very High Very High
Onset of action 14 99.14 Very High Very High Very High
antagonist 21 98.96 Very High Very High Very High
peptic ulcer disease 7 95.60 Very High Very High Very High
diclofenac 5 89.84 High High
Inflammation 26 89.12 High High
Paracetamol 22 86.00 High High
Pain 83 85.12 High High
Osteoarthritis 29 84.92 Quite High
aspirin 29 74.72 Quite High
Disease Link Frequency Relevance Heat
Disease 150 99.62 Very High Very High Very High
Gastroesophageal Reflux Disease 765 98.04 Very High Very High Very High
Recurrence 126 97.32 Very High Very High Very High
Esophageal Disease 112 95.84 Very High Very High Very High
Ulcers 147 95.60 Very High Very High Very High
Toxicity 4 93.96 High High
Peptic Ulcer 17 90.52 High High
INFLAMMATION 31 89.12 High High
Acid Reflux 105 85.84 High High
Pain 84 85.12 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Two patterns consisting of continuation of an NSAID plus administration of the prostaglandin (PG) preparation misoprostol (PG model) for 8 weeks and continuation of an NSAID plus administration of the proton-pump inhibitors omeprazole and lansoprazole (PPI model) for 8 weeks were examined.
Negative_regulation (inhibitors) of proton-pump associated with cinod
1) Confidence 0.35 Published 2008 Journal Yakugaku Zasshi Section Abstract Doc Link 18379175 Disease Relevance 0.49 Pain Relevance 0.51
The response to treatment with proton-pump inhibitors in patients with reflux disease, but not in those without, underlined the critical role of acid reflux in a subset of patients with 'non-cardiac chest pain'.


Negative_regulation (inhibitors) of proton-pump in chest
2) Confidence 0.35 Published 2009 Journal J. Gastroenterol. Hepatol. Section Body Doc Link 19054255 Disease Relevance 0.06 Pain Relevance 0
GI complications can be reduced by using lower NSAID doses for the shortest duration or with a concomitant proton-pump inhibitor.
Negative_regulation (inhibitor) of proton-pump associated with cinod
3) Confidence 0.00 Published 2009 Journal Osteopath Med Prim Care Section Abstract Doc Link PMC2646740 Disease Relevance 0.92 Pain Relevance 1.34
Proton pump inhibitors are indicated in the management of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcer disease, in association with Helicobacter pylori eradication therapy when needed.
Negative_regulation (inhibitors) of Proton pump associated with peptic ulcer disease, ulcers, gastroesophageal reflux disease and disease
4) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.54 Pain Relevance 0.10
Rabeprazole is a proton pump inhibitor (PPI) and as such covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase).
Negative_regulation (inactivates) of proton pump in parietal cell
5) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.47 Pain Relevance 0.08
Rabeprazole is a proton pump inhibitor (PPI) and as such covalently binds with and inactivates the gastric parietal cell proton pump (H+/K+-ATPase).
Negative_regulation (inhibitor) of proton pump in parietal cell
6) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.38 Pain Relevance 0.08
Standard exclusion criteria included recent treatment with therapeutic doses of a proton pump inhibitor or histamine H2-receptor antagonist, concurrent systemic disorders and medical conditions that would prevent endoscopy.
Negative_regulation (inhibitor) of proton pump associated with antagonist
7) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.85 Pain Relevance 0.05
A review of rabeprazole in the treatment of acid-related diseases

Rabeprazole is a proton pump inhibitor.

Negative_regulation (inhibitor) of proton pump associated with disease
8) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Title Doc Link PMC2386363 Disease Relevance 0.36 Pain Relevance 0
In an isolated hog vesicle model, rabeprazole confirmed its potent and fast onset of action: within 5 min of rabeprazole exposure the proton pump was near-maximally inhibited.
Negative_regulation (inhibited) of proton pump in vesicle associated with onset of action
9) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.11 Pain Relevance 0.05
Considering that few trials of proton pump inhibitors in maintaining healing of erosive or ulcerative GERD are conducted for longer than 1 year, Thjodleifsson and colleagues in 2003 (Thjodleifsson et al 2003) published the comparison of the efficacy and safety of 2 doses of rabeprazole with 20 mg omeprazole in the maintenance treatment of erosive GERD over 5 years.
Negative_regulation (inhibitors) of proton pump associated with gastroesophageal reflux disease
10) Confidence 0.00 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386363 Disease Relevance 0.96 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox